quinoxalines has been researched along with ATLL in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishikawa, C; Mori, N; Senba, M | 1 |
| Bazarbachi, A; Bonnet, PA; Deleuze-Masquéfa, C; El-Hajj, H; El-Sabban, ME; Hermine, O; Kfoury, Y; Lepelletier, Y; Moarbess, G | 1 |
2 other study(ies) available for quinoxalines and ATLL
| Article | Year |
|---|---|
Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Topics: Animals; CDC2 Protein Kinase; Cell Line, Tumor; Coculture Techniques; Cyclin B1; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Leukemia-Lymphoma, Adult T-Cell; Leukocytes, Mononuclear; Mice; Mitogen-Activated Protein Kinase Kinases; Neoplasm Transplantation; Phosphorylation; Quinoxalines; Up-Regulation | 2018 |
EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspases; Cell Division; Cytochromes c; G2 Phase; Human T-lymphotropic virus 1; Humans; Imiquimod; Inflammation; Inhibitor of Apoptosis Proteins; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Lymphocyte Activation; Lymphoma, T-Cell; Membrane Potential, Mitochondrial; NF-kappa B; Quinoxalines; Skin Neoplasms; Tumor Suppressor Protein p53 | 2008 |